key: cord-0964948-affgkqyb
authors: Mohan, Meera; Nagavally, Sneha; Shah N, Nirav N; Michaelis, Laura; Chhabra, Saurabh; Souza, Anita D; Abedin, Sameem; Runaas, Lyndsey; Guru Murthy, Guru Subramanian; Longo, Walter; Hamadani M, Mehdi; Dhakal, Binod; Hari, Parameswaran; Fenske, Timothy S
title: Shorter Interval between Treatment and COVID Immunization is Associated with Poor Seroconversion in Patients with Hematological Malignancies
date: 2022-01-19
journal: Clin Lymphoma Myeloma Leuk
DOI: 10.1016/j.clml.2022.01.010
sha: 095c5c0d0e5b189eb6b4782ba6a87b7c7d8c0a1d
doc_id: 964948
cord_uid: affgkqyb

nan

References: 15

To the editor,Cancer patients are disproportionately affected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection resulting in significant morbidity and mortality [1] [2] [3] . Emerging evidence suggest that patients with cancer, and particularly those with hematological malignancies, have an attenuated or delayed response to immunization [4, 5] . Herein, we report antibody responses to SARS-CoV-2 vaccination in patients with various hematological malignancies. In the current study we retrospectively assessed SARs-CoV-2 spike binding IgG antibody levels using the EUROIMMUN assay [6] . Clinical data was extracted from medical records, and date of administration of second dose of Pfizer/Moderna vaccine and date of J&J vaccine was captured. Cancer treatment was broadly divided into chemotherapy, monoclonal antibodies (MoAb), small molecules (such as BTKi, BCL2 inhibitor, TKI etc) and others. For this analysis, the last IgG level prior to receiving SARS-CoV-2 vaccine recorded in the medical records was captured when available. Hypogammaglobinemia and severe hypogammaglobinemia were defined as ≤700 mg/dl and ≤400 mg/dl, respectively. Intravenous immunoglobulin (IVIG) replacement was done at the discretion of the treating physician.

In this analysis, 149 patients across a broad range of hematological malignancies were included.

The median age was 70 (range 61-74) years with 67.8% (n=101) ≥ 65 years of age ( Table 1) . The distribution of hematological cancer was as follows with chronic lymphocytic leukemia (CLL) and B cell non-Hodgkin's lymphoma (NHL) accounting for 27.5% (n=41) and 44% (n=62) of patients, respectively.

MPN accounted for 12.1% (n=18) and PCD 8.1% (n=12) of cases. Among these, 30% (n=40) of patients were in clinical remission. Among patients who had received maintenance therapy, 12 were still on maintenance and 18 had completed maintenance therapy, at a median of median of 8.4 months before COVID 19 immunization. About 10% (n=15) of patients were under active surveillance and were never treated for their malignancy. A total of 69 patients received monoclonal antibody-based therapy targeting There was a predominance of hypogammaglobinemia (70.7% vs 47.6%; p=0.03) and severe hypogammaglobinemia (26.8% vs 9.5%, p= 0.049) in seronegative group. IVIG supplementation was prescribed in 2.7% (4.7% vs 1.2%) of all patients.

Seroconversion among patients with hypogammaglobulinemia and severe hypogammaglobulinemia, were 47.6% (n=20) and 9.5% (n=4), respectively. On multivariate analysis, male sex (HR 0.51, 95% CI 0.26-0.98; p=0.05), diagnosis of B cell lymphomas (HR 0.46, 95% CI 0.23-0.92; p=0.03), use of MoAb (HR 0.14, 95% CI 0.02-0.62; p=0.02) and baseline hypogammaglobinemia (HR 0.38, 95% CI 0.15-0.92; p=0.04) were independently associated with poor seroconversion. Patients who received COVID19 vaccination at least 3 months after their last treatment were 4.64 (95% CI 2.02-11.43; p=0.0005) times more likely to mount a vaccine response, compared to those patients who were never treated. Similarly, patients who were vaccinated at least 3 months after their last treatment were 6.5 (95% CI 2.39-19.13; p=0.0004) times more likely to seroconvert.

Overall, in this series more than half of the patients remained seronegative, with an overwhelming two thirds of the patients on anti-CD20 MoAb unable to mount an antibody response. Consistent with previous reports, we observed lower rates of seroconversion in certain cancer types like CLL with inherent defects in humoral immunity, in patients on active therapy (≤3 months since completion of therapy), and those receiving anti-CD 20 MoAb based therapy [7, 8] . Patients who seroconverted had antibody titers measured later (9.7 vs 6.0 weeks) compared to those who were seronegative. While this might suggest a delayed immune response, it is plausible that this group of patients were more likely to be in clinical remission, and off active cancer therapy, and being followed less closely and therefore may have had a longer interval from vaccination until antibody testing. Limitations of this study include a heterogenous population with different cancer diagnoses and thus different treatment regimens. In addition, long-term follow up to assess for actual rates of SARS-CoV-2 infection or serious infection post immunization was not captured [9] . Several crucial questions such the optimal timing and dosing schedule of vaccination, the efficacy of booster doses in seropositive and seronegative cancer patients, and infection mitigation strategies such as prophylactic use of MoAb cocktails in seronegative groups, all remain to be addressed in future clinical trials. 

COVID-19 and Cancer: Current Challenges and Perspectives

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. The Lancet

Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium

Seroconversion rates following COVID-19 vaccination among patients with cancer

Patterns of seroconversion for SARS-CoV-2 IgG in patients with malignant disease and association with anticancer therapy

Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates